Clinical trial
De Novo Sirolimus-based Immunosuppression After Liver Transplantation for…
NCT00328770 · University of Alberta, Other · Completed
Key facts
| NCT number | NCT00328770 |
|---|---|
| Title | De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma |
| Official title | De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma: Long-Term Outcomes and Side Effects |
| Lead sponsor | University of Alberta, Other |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Liver Carcinoma |
| Intervention type | Drug |
| Interventions | Sirolimus |
| Enrollment | 70 |
| Start date | Dec 1, 1996 |
| Primary completion | Mar 1, 2006 |
| Completion | Mar 1, 2006 |
| First posted | May 22, 2006 |
| Last update posted | Jun 24, 2013 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: